Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C, Thalassinos N
Department of Endocrinology, Diabetes and Metabolism, Evangelismos' Hospital, Athens, Greece.
Clin Endocrinol (Oxf). 1998 Aug;49(2):165-71. doi: 10.1046/j.1365-2265.1998.00509.x.
It has recently been suggested that autonomous cortisol production may lead to subclinical glucocorticoid excess in a substantial number of patients with incidentally discovered adrenocortical adenomas. Following a standard low-dose dexamethasone suppression test (LDDST) cortisol concentrations are frequently incompletely suppressed in patients with adrenal incidentalomas, due to an ACTH-independent secretion of cortisol by the adrenal mass. Thus, post LDDST cortisol concentrations may provide a measure of the degree of autonomous glucocorticoid secretion, but hormonal alterations in relation to post-LDDST cortisol concentrations have not been thoroughly investigated.
61 patients with radiological features highly suggestive of adrenal adenomas were studied. These included 43 women, 18 men; mean age 59 +/- 1.4, range: 25-76 years; BMI 30.9 +/- 0.8 kg/m2 and waist:hip ratio 0.90 +/- 0.016. All subjects underwent a standard LDDST, as follows: after a 48-hr stabilisation period, 24-hr urine collections for basal urinary free cortisol (UFC) were performed. Basal serum cortisol and plasma ACTH were measured at 8 AM and at midnight the following day, and subjects started dexamethasone 0.5 mg 6 hourly for 2 days. Post-dexamethasone cortisol and ACTH levels were measured at 8 AM, 6-hrs after the last dose of dexamethasone. Blood samples for dehydroepiandrosterone sulphate (DHEAS) and serum lipids were obtained on the morning preceding dexamethasone administration.
Post-LDDST cortisol concentrations correlated positively with the size of the adenoma (r = +0.527, P < 0.001). There was a negative rank correlation of post-LDDST cortisol concentrations and basal ACTH levels at 0900 h (rs = -0.426, P < 0.001) and DHEAS (rs = -0.380, P = 0.006). Moreover, there was a good rank correlation between DHEAS and basal ACTH levels (rs = +0.456, P < 0.001). A positive rank correlation was observed between post-LDDST cortisol concentrations and midnight cortisol concentrations (rs = +0.317, P = 0.020). As recent studies have suggested that post-LDDST cortisol levels higher than 70 nmol/l may indicate significant hypercortisolism comparisons were also performed between patients divided according to post-LDDST cortisol values into 3 groups: Group A, > 70 nmol/l (19 pts); Group B, 30-70 nmol/l (27 pts); Group C, < 30 nmol/l (15 pts). Although there was no difference in basal cortisol and UFC values between these groups, ACTH and DHEAS levels were significantly lower, and midnight cortisol significantly higher in group A compared to group C patients (P = 0.030, P = 0.017 and P = 0.001 respectively). Cholesterol and triglyceride levels were slightly albeit significantly higher in group A compared to group C patients (P < 0.05).
It is concluded that higher post-low dose dexamethasone cortisol concentrations are associated with lower ACTH and dehydroepiandrosterone sulphate, higher midnight cortisol concentrations and larger adenomas. These findings are consistent with the hypothesis that post-low dose dexamethasone cortisol concentrations represent a useful index in assessing subtle glucocorticoid autonomy in patients with adrenal adenomas.
最近有人提出,在大量偶然发现肾上腺皮质腺瘤的患者中,自主性皮质醇分泌可能导致亚临床糖皮质激素过多。在标准低剂量地塞米松抑制试验(LDDST)后,肾上腺意外瘤患者的皮质醇浓度常常不能被完全抑制,这是由于肾上腺肿物可独立于促肾上腺皮质激素(ACTH)分泌皮质醇。因此,LDDST后的皮质醇浓度可能提供了一种衡量自主性糖皮质激素分泌程度的指标,但与LDDST后皮质醇浓度相关的激素变化尚未得到充分研究。
对61例具有高度提示肾上腺腺瘤影像学特征的患者进行了研究。其中包括43名女性,18名男性;平均年龄59±1.4岁,范围:25 - 76岁;体重指数(BMI)30.9±0.8kg/m²,腰臀比0.90±0.016。所有受试者均接受了标准的LDDST,具体如下:在48小时稳定期后,进行24小时尿液收集以检测基础尿游离皮质醇(UFC)。在上午8点和次日午夜测量基础血清皮质醇和血浆ACTH,受试者开始每6小时服用0.5mg地塞米松,共服用2天。在最后一剂地塞米松服用6小时后的上午8点测量地塞米松后的皮质醇和ACTH水平。在服用地塞米松前一天上午采集血样检测硫酸脱氢表雄酮(DHEAS)和血脂。
LDDST后的皮质醇浓度与腺瘤大小呈正相关(r = +0.527,P < 0.001)。LDDST后的皮质醇浓度与上午9点的基础ACTH水平(rs = -0.426,P < 0.001)和DHEAS(rs = -0.380,P = 0.006)呈负等级相关。此外,DHEAS与基础ACTH水平之间存在良好的等级相关(rs = +0.456,P < 0.001)。LDDST后的皮质醇浓度与午夜皮质醇浓度呈正等级相关(rs = +0.317,P = 0.020)。由于最近的研究表明,LDDST后皮质醇水平高于70nmol/l可能表明存在明显的皮质醇增多症,因此还根据LDDST后的皮质醇值将患者分为3组进行比较:A组,> 70nmol/l(19例);B组,30 - 70nmol/l(27例);C组,< 30nmol/l(15例)。尽管这些组之间的基础皮质醇和UFC值没有差异,但与C组患者相比,A组患者的ACTH和DHEAS水平显著降低,午夜皮质醇显著升高(分别为P = 0.030,P = 0.017和P = 0.001)。与C组患者相比,A组患者的胆固醇和甘油三酯水平略高但有显著差异(P < 0.05)。
得出结论,低剂量地塞米松后较高的皮质醇浓度与较低的ACTH和硫酸脱氢表雄酮、较高的午夜皮质醇浓度以及较大的腺瘤相关。这些发现与以下假设一致,即低剂量地塞米松后的皮质醇浓度是评估肾上腺腺瘤患者细微糖皮质激素自主性的一个有用指标。